Consensus Statement on the Management of Duchenne Muscular Dystrophy in Saudi Arabia During the Coronavirus Disease 2019 Pandemic
Open Access
- 17 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9, 629549
Abstract
Background:The coronavirus disease 2019 (COVID-19) pandemic has caused overwhelming challenges in healthcare worldwide. During such an outbreak, some needs of high-risk groups who require regular follow-ups and long-term management are not met. The vulnerable populations include patients with Duchenne muscular dystrophy (DMD). Duchenne muscular dystrophy is characterized by respiratory complications caused by muscle weakness. Hence, patients with this condition are at high risk of severe diseases including COVID-19.Methods:To standardize care and provide optimal treatment to DMD patients in Saudi Arabia during the COVID-19 pandemic, a panel of experts including neurologists and pediatricians consolidated recommendations for healthcare professionals and caregivers.Results:During this pandemic, substituting unnecessary clinic visits with virtual clinic services was highly recommended, if possible, without compromising clinical outcomes. Duchenne muscular dystrophy patients with respiratory complications should be closely monitored, and those with cardiovascular complications must continue taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Moreover, individualized home-based rehabilitation management was preferred. Glucocorticoid and new gene correction therapies should be continued. However, new gene correction therapy must be post-poned in newly diagnosed patients. A multidisciplinary decision was required before the initiation of hydroxychloroquine based on the COVID-19 treatment protocol.Conclusion:COVID-19 has caused challenges and transformed access to health care. However, these limitations have provided opportunities for the health care system to adapt. Further, telemedicine has become a reliable platform for follow-up appointments that should be conducted by a multidisciplinary team including physicians, dieticians, and physical therapists.Keywords
This publication has 28 references indexed in Scilit:
- Case Studies in Physical Therapy: Transitioning a "Hands-On" Approach into a Virtual PlatformInternational Journal of Telerehabilitation, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic managementThe Lancet Neurology, 2018
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementThe Lancet Neurology, 2018
- A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult SubjectsThe Journal of Clinical Pharmacology, 2017
- Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMDMolecular Therapy, 2011
- Quality Assurance for Duchenne and Becker Muscular Dystrophy Genetic TestingThe Journal of Molecular Diagnostics, 2011
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial managementThe Lancet Neurology, 2010
- Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft‐versus‐host diseaseAmerican Journal of Hematology, 2005
- Dystrophin: The protein product of the duchenne muscular dystrophy locusCell, 1987
- Becker‐type muscular dystrophyMuscle & Nerve, 1978